Raymond Wilfred W, Su Sharon, Makarova Anastasia, Wilson Todd M, Carter Melody C, Metcalfe Dean D, Caughey George H
Cardiovascular Research Institute, University of California at San Francisco, San Francisco, CA 94143, USA.
J Immunol. 2009 May 1;182(9):5770-7. doi: 10.4049/jimmunol.0900127.
Human chymase is a highly efficient angiotensin II-generating serine peptidase expressed by mast cells. When secreted from degranulating cells, it can interact with a variety of circulating antipeptidases, but is mostly captured by alpha(2)-macroglobulin, which sequesters peptidases in a cage-like structure that precludes interactions with large protein substrates and inhibitors, like serpins. The present work shows that alpha(2)-macroglobulin-bound chymase remains accessible to small substrates, including angiotensin I, with activity in serum that is stable with prolonged incubation. We used alpha(2)-macroglobulin capture to develop a sensitive, microtiter plate-based assay for serum chymase, assisted by a novel substrate synthesized based on results of combinatorial screening of peptide substrates. The substrate has low background hydrolysis in serum and is chymase-selective, with minimal cleavage by the chymotryptic peptidases cathepsin G and chymotrypsin. The assay detects activity in chymase-spiked serum with a threshold of approximately 1 pM (30 pg/ml), and reveals native chymase activity in serum of most subjects with systemic mastocytosis. alpha(2)-Macroglobulin-bound chymase generates angiotensin II in chymase-spiked serum, and it appears in native serum as chymostatin-inhibited activity, which can exceed activity of captopril-sensitive angiotensin-converting enzyme. These findings suggest that chymase bound to alpha(2)-macroglobulin is active, that the complex is an angiotensin-converting enzyme inhibitor-resistant reservoir of angiotensin II-generating activity, and that alpha(2)-macroglobulin capture may be exploited in assessing systemic release of secreted peptidases.
人糜蛋白酶是一种由肥大细胞表达的高效生成血管紧张素II的丝氨酸蛋白酶。当从脱颗粒细胞分泌时,它可以与多种循环抗肽酶相互作用,但大多被α2-巨球蛋白捕获,α2-巨球蛋白将肽酶隔离在笼状结构中,阻止其与大的蛋白质底物和抑制剂(如丝氨酸蛋白酶抑制剂)相互作用。目前的研究表明,与α2-巨球蛋白结合的糜蛋白酶对于包括血管紧张素I在内的小底物仍可接近,在血清中的活性在长时间孵育后保持稳定。我们利用α2-巨球蛋白捕获技术,结合基于肽底物组合筛选结果合成的新型底物,开发了一种基于微孔板的血清糜蛋白酶敏感检测方法。该底物在血清中的背景水解率低,对糜蛋白酶具有选择性,被组织蛋白酶G和胰凝乳蛋白酶等胰蛋白酶样肽酶切割的程度最小。该检测方法检测加标血清中糜蛋白酶活性的阈值约为1 pM(30 pg/ml),并揭示了大多数系统性肥大细胞增多症患者血清中的天然糜蛋白酶活性。与α2-巨球蛋白结合的糜蛋白酶在加标血清中生成血管紧张素II,在天然血清中以抑糜酶抑制的活性形式出现,其活性可能超过卡托普利敏感的血管紧张素转换酶的活性。这些发现表明,与α2-巨球蛋白结合的糜蛋白酶具有活性,该复合物是生成血管紧张素II活性的一种抗血管紧张素转换酶抑制剂的储备库,并且α2-巨球蛋白捕获技术可用于评估分泌性肽酶的全身释放。